Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience

Rearrangement in the anaplastic lymphoma kinase (ALK) gene is one of the oncogenic drivers in non-small cell lung cancer (NSCLC) patients. Several ALK inhibitors (ALKis) have been developed and have demonstrated their efficacy, however the best treatment strategy for ALK positive NSCLC patients has...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: De Carlo, Elisa, Del Savio, Maria Chiara, Polesel, Jerry, Da Ros, Valentina, Berto, Eleonora, Santarossa, Sandra, Chimienti, Emanuela, Fratino, Lucia, Bearz, Alessandra
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2018
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5880608/
https://ncbi.nlm.nih.gov/pubmed/29632648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24573
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky